EKR Therapeutics, Inc. Receives Notice of Patent Allowance for Ready-to-Use Cardene(R) I.V. Bags, a Specialty Product Line for Treating Acute Hypertension in Emergency and Critical-Care Settings

BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that it received notice of patent allowance from the U.S. Patent and Trademark Office for its Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.